Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Kyle Degeyter

Vascular & Interventional Radiology Lafayette, LA Medical Doctor

NPI 1083840888 CMS profile 1393263

4801 Ambassador Caffery Pkwy, Lafayette, LA 70508

Open in the dashboard

General payments

$27,273

236 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Kyle Degeyter of Lafayette, LA is reported in the CMS Open Payments database as having received $27,273 across 236 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 87th percentile of Vascular & Interventional Radiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,140 48
2024 General $8,438 35
2023 General $8,296 47
2022 General $1,424 30
2021 General $804 23
2020 General $843 18
2019 General $4,328 35

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Kyle Degeyter
  • Vascular & Interventional Radiology median
  • Middle half of Vascular & Interventional Radiology
  • National median

In program year 2025, general payments to Kyle Degeyter were reported at $3,140. Among 3,393 Vascular & Interventional Radiology profiles paid that year, the median was $534 and the middle half received between $166 and $2,075.

Show as a table
Year Kyle Degeyter Vascular & Interventional Radiology median Middle half National median
2019 $4,328 $422 $125–$1,555 $163
2020 $843 $200 $68–$652 $114
2021 $804 $280 $99–$866 $132
2022 $1,424 $433 $137–$1,497 $149
2023 $8,296 $506 $152–$2,019 $160
2024 $8,438 $556 $175–$1,930 $164
2025 $3,140 $534 $166–$2,075 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Medtronic, Inc. $7,478 38 payments
  2. Surefire Medical, Inc. $5,384 24 payments
  3. Boston Scientific Corporation $4,632 75 payments
  4. Penumbra, Inc. $3,476 18 payments
  5. Stryker Corporation $1,323 8 payments
  6. Sirtex Medical Inc $1,205 18 payments
  7. Terumo Medical Corporation $966 10 payments
  8. Inari Medical, Inc. $517 8 payments
  9. Imperative Care, INc $475 7 payments
  10. Shockwave Medical, Inc $301 2 payments
  11. Other $1,516 28 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Travel and Lodging $12,578 36 payments
  2. Food and Beverage $11,605 198 payments
  3. Honoraria $3,000 1 payment
  4. Education $90 1 payment
Products named General payments · program years 2019–2025
  1. HawkOne $5,987 6 payments
  2. TRINAV INFUSION SYSTEM $5,384 24 payments
  3. Indigo System $2,419 13 payments
  4. IVS - VERTEBRAL AUGMENTATION PRODUCTS $1,122 5 payments
  5. SIR-Spheres Microspheres $898 15 payments
  6. Penumbra System $892 2 payments
  7. Glidesheath $839 7 payments
  8. GlideWire $749 6 payments
  9. Navicross $749 6 payments
  10. ANGIOJET $739 7 payments
  11. Other $9,239 150 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 2 drugs

Part D claims

25

Median for Diagnostic Radiology: 24

Drug cost

$93

Median for Diagnostic Radiology: $190

Branded share of claims

0%

Median for Diagnostic Radiology: 0%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Metoclopramide Hcl Generic 11 $87
Prednisone Generic 14 $7

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 1,198 Part D prescribers listed as Diagnostic Radiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 158 billing codes

Paid by Medicare

$72,873

Medicare's payments for the services billed

Medicare patients

1,130

Average age 74

Services billed

1,687

688 women, 442 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 53%
Ischemic heart disease 47%
Diabetes 39%
Depression 36%
Chronic kidney disease 35%
Atrial fibrillation 31%
Heart failure 30%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

2 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
KEYTRUDA
  • Merck Sharp & Dohme Corporation $7
$7 — —
LYNPARZA
  • Merck Sharp & Dohme Corporation $7
$7 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

236 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record